Table 2 Current selected clinical trials on NB

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

Radiation: 124I-MIBG (no-carrier added)

Radiation: 124I-MIBG (carrier added)

https://ClinicalTrials.gov/show/NCT01583842

European Low and Intermediate Risk Neuroblastoma Protocol (low and intermediate pediatric NB and neonatal suprarenal masses)

Drug: chemotherapy

https://ClinicalTrials.gov/show/NCT01728155

Phase II Study of Proton Radiation Therapy for Neuroblastoma

Radiation: proton beam radiation therapy

https://ClinicalTrials.gov/show/NCT02112617

Immunomonitoring of Children With Neuroblastoma

Immunological analyses

https://ClinicalTrials.gov/show/NCT01295762

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH

https://ClinicalTrials.gov/show/NCT00911560

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Laboratory biomarker analysis; cytology specimen collection procedure

https://ClinicalTrials.gov/show/NCT00904241

Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma

Drug: dasatinib

Drug: rapamycin

Drug: irinotecan

Drug: temozolomide

Drug: irinotecan

Drug: temozolomide

https://ClinicalTrials.gov/show/NCT01467986

Study of DNA in Blood Samples From Patients With Neuroblastoma

Laboratory biomarker analysis

Genetic: polymerase chain reaction

Genetic: polyacrylamide gel electrophoresis

Genetic: DNA analysis

https://ClinicalTrials.gov/show/NCT00898391

Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine-Positron Emission Tomography (FLT-PET)

Device: FLT-PET

https://ClinicalTrials.gov/show/NCT01308905

Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma

Drug: fenretinide Lym-X-Sorb oral powder

Drug: ketoconazole

https://ClinicalTrials.gov/show/NCT02075177

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults with Neuroblastoma and Osteosarcoma

Biological: IL-2

Biological: GD2Bi-aATC

Biological: GM-CSF

Other: laboratory evaluations of immune responses

https://ClinicalTrials.gov/show/NCT02100930

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

Biological: anti-GD2 3F8 monoclonal antibody

Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor)

Drug: oral isotretinoin

https://ClinicalTrials.gov/show/NCT02100930

Fenretinide Lym-X-Sorb+Ketoconazole+Vincristine for Recurrent or Resistant Neuroblastoma

Drug: fenretinide/LXS oral powder

Drug: ketoconazole

Drug: vincristine

https://ClinicalTrials.gov/show/NCT02163356

Pilot Study of Activated T-Cell Therapy for Refractory/Relapsed Neuroblastoma

Biological: activated T lymphocyte

https://ClinicalTrials.gov/show/NCT01802138

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Genetic: iC9-GD2 T-cell lymphocytes – frozen cells

Genetic: iC9-GD2 T-cell lymphocytes – fresh cells

Drug: cyclophosphamide

Drug: fludarabine

Drug: pembrolizumab

https://ClinicalTrials.gov/show/NCT01822652